Liver Failure Clinical Trial
Official title:
A Multicenter, Randomized, Controlled, Open-Label Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of HepaCure Plus DPMAS Versus DPMAS Alone in Chinese Subjects With Acute-On-Chronic Liver Failure
This is a multicenter, randomized, controlled, open-label phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure(ACLF). Phase 1 is a multicenter, open label study to evaluate the safety and tolerability of single dose and multiple doses of HepaCure with different treatment duration plus DPMAS in ACLF subjects respectively.
Status | Recruiting |
Enrollment | 12 |
Est. completion date | September 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Able to communicate effectively with investigators and sign the informed consent form (ICF) voluntarily. 2. Age: = 18 years and = 65 years. 3. Body weight: = 40kg; 4. Met the criteria of ACLF in the early and middle stages in screening period (Guidelines for the Diagnosis and Treatment of Liverfilture (2018 Edition)): base on chronic liver disease, acute jaundice deepened and coagulation dysfunction caused by various inducements, manifested as extreme fatigue, with obvious gastrointestinal symptoms such as anorexia, vomiting, abdominal distention, etc; Progressive deepening of jaundice, serum TBil = 171 µmol/L or increase = 17.1 µmol/L daily; with bleeding tendencies or manifestations (bleeding spots or ecchymosis), or 20%<PTA = 40% (or 1.5 = INR<2.6), and other reasons excluded. Exclusion Criteria: 1. Subjects with primary or metastatic liver cancer. 2. Subjects with severe esophageal/gastric varices and high risk of bleeding, with positive red signs, or with previous active bleeding, as indicated by gastroscopy or imaging examination results. 3. Pneumonia refer to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (after reasonable antibiotic treatment, there are still Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L), etc. 4. Subjects with serious uncontrolled infections, including sepsis, septic shock, severe pneumonia (refers to the diagnostic criteria of the American Society of Infectious Diseases/American Thoracic Society for adult severe pneumonia in 2007), abdominal infection (exist Peritonitis manifestations or white blood cells in ascites>0.1 × 10 9/L after reasonable antibiotic treatment), etc; |
Country | Name | City | State |
---|---|---|---|
China | Beijing You'an Hospital affiliated to Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Hexaell Biotech Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety outcome | The adverse events (AE), Serious adverse event (SAE), adverse events of special concern (AESI), and device defects (leakage caused by the quality problem of the plasma biological purification column itself) of the safety paramater will be collected, and the safety and tolerability within 14 days and 28 days will be evaluated from the end of the last treatment | 28 days after the end of last treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03791190 -
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
|
N/A | |
Completed |
NCT02557724 -
Mobilization of Mesenchymal Stem Cells During Liver Transplantation
|
||
Recruiting |
NCT01698723 -
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus
|
Phase 2 | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT01404793 -
SPME For Metabolomics And Concomitant Measurements Of Rocuronium Bromide Levels In Liver Transplantation
|
N/A | |
Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
Completed |
NCT03864497 -
Myocardial Perfusion Imaging in Liver Transplantation Candidates
|
||
Completed |
NCT00287235 -
Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
|
N/A | |
Completed |
NCT03650920 -
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
|
N/A | |
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05726032 -
Empagliflozin in Patients With Cirrhosis and Ascites
|
Phase 2 | |
Recruiting |
NCT04548596 -
NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
|
||
Recruiting |
NCT02331745 -
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
|
Phase 4 | |
Not yet recruiting |
NCT01961440 -
Prognosis Scoring System for Acute-on-Chronic Liver Failure
|
N/A | |
Active, not recruiting |
NCT01221454 -
Allogenic Bone Marrow Stem Cell Transplantation in Liver Failure
|
Phase 2 | |
Completed |
NCT00772148 -
Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
|
Phase 2 | |
Completed |
NCT05592106 -
Gd-EOB-DTPA-enhanced T1 Map for Predicting Postoperative Liver Failure
|
||
Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|
||
Recruiting |
NCT04221672 -
The Effect of Terlipressin on Recovery of Liver Function After Hepatectomy
|
Phase 3 | |
Withdrawn |
NCT02552901 -
Cardiox Liver Function Test Pivotal Trial
|
Phase 3 |